GC
RVMD icon

Grace Capital’s Revolution Medicines RVMD Stock Holding History

Grace Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,555
Closed -$208K – 173
2021
Q2 		$208K Hold
6,555
– – 0.14% 129
2021
Q1 		$301K Buy
+6,555
New +$294K 0.19% 129

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grace Capital's RVMD Position: Q3 2021 in Review

Grace Capital sold out of Revolution Medicines (RVMD) in Q3 2021, closing a stake of 6,555 shares — an estimated $208K sold.

Grace Capital first reported a position in RVMD in Q1 2021 and held it in 2 quarters. The position peaked at $301K in Q1 2021. 114 funds tracked by Wall St. Rank hold RVMD as of Q3 2021.

  • Grace Capital reported no remaining Revolution Medicines position as of Q3 2021 after selling out during the quarter.
  • Grace Capital sold 6,555 Revolution Medicines shares in Q3 2021, an estimated $208K.
  • Grace Capital first reported a position in Revolution Medicines in Q1 2021 and held it in 2 quarters.
  • Grace Capital's Revolution Medicines position peaked at $301K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2021.

Based on Grace Capital's 13F filing for Q3 2021, filed 8 Nov 2021.